INTRODUCTION {#s1}
============

Ovarian cancer, with only a 45% 5-year survival rate, remains one of the most devastating malignancies for women \[[@R1]\]. Most tumors are diagnosed at advanced stages; thus, there remains a necessity for new therapeutic targets that are effective in the context of progressive disease, as well as identification of markers that would improve clinical management of affected women.

Epidermal growth factor receptor (EGFR) is a key signaling molecule that drives cellular proliferation, migration, and invasion \[[@R2]\]. Selective EGFR inhibitors have been recommended as first-line therapy in lung cancer patients harboring EGFR mutations \[[@R3]-[@R5]\], and have also shown modest effectiveness against tumors of the pancreas \[[@R6], [@R7]\] Identification that EGFR is expressed in up to 90% of certain histotypes of ovarian tumors led to investigation of this molecule as a potential prognostic biomarker as well as therapeutic target in ovarian cancer \[[@R8], [@R9]\]. Unfortunately, response to EGFR-targeted tyrosine kinase-based inhibitors (TKIs) in unselected ovarian cancer patient populations has not been encouraging, with 0-6% response rates in patients with persistent or recurrent disease \[[@R10]-[@R12]\], and no significant survival benefit as a maintenance therapy for patients with response or stable disease after first-line chemotherapy \[[@R13]\].

The high EGFR expression found in ovarian tumors \[[@R8]\] and known ability of this pathway to drive tumor cell proliferation and dissemination remain compelling reasons to continue to pursue EGFR inhibitors for ovarian cancer therapy, yet the poor results seen in clinical trials to date point to a need for better methods for patient selection and stratification. Relevant criteria that may be useful in identifying responders may include histological features or molecular subtypes, disease stage, chemoresistance, as well as evidence for the expression and activation of EGFR itself.

Here we have assessed EGFR expression levels in patient-derived tissue microarrays using one of the largest, single institution ovarian cancer patient cohorts to date. We have evaluated protein staining intensity and localization, and have assessed potential significant associations with tumor stage, survival, and histology. We present our results in the context of the current literature focusing on EGFR as a biomarker in ovarian cancer. By evaluating differences and similarities in relation to our own findings, we critically discuss the suitability of EGFR staining as a biomarker and consider possible alternatives that may be more promising as prognostic biomarkers and as potential predictive markers to stratify patients for EGFR inhibitor treatment.

RESULTS {#s2}
=======

Clinical characteristics {#s2_1}
------------------------

From 570 patient samples, after excluding patient samples with missing data, undetermined histology, or missing tumor tissue, tissue samples representing 488 patients were included in the analysis (Table [1](#T1){ref-type="table"}). The age range at diagnosis was between 21 and 93 years. Histological distribution of the tumors was similar to that reported for other cohorts \[[@R14]\] (high-grade serous 72.3%, endometrioid 13.7%, clear cell 6.4%, mucinous 3.3%, low grade serous 0.6%, mixed histology 3.7%). A substantial proportion (85%) of the patients presented with grade 3 disease. At a median follow-up of 116 months (range: 1-187), 339 patients (69.5%) had died. The median overall survival for the cohort was 57.8 months (95% CI: 48.4-67.5).

###### Patient Characteristics

                                             Total (N = 488)
  ------------------------------------------ -----------------
  **Age at Diagnosis, years**                 
   N                                         488
   Mean (SD)                                 61.4 (12.5)
   Median                                    61.0
   Q1, Q3                                    52.0, 71.0
   Range                                     (21.0-93.0)
  **Histology**                               
   High Grade Serous                         353 (72.3%)
   Low Grade Serous                          3 (0.6%)
   Mucinous                                  16 (3.3%)
   Endometrioid                              67 (13.7%)
   Clear Cell                                31 (6.4%)
   Mixed                                     18 (3.7%)
  **Stage**                                   
   1                                         79 (16.2%)
   2                                         33 (6.8%)
   3                                         299 (61.3%)
   4                                         77 (15.8%)
  **Grade**                                   
   1                                         31 (6.4%)
   2                                         42 (8.6%)
   3                                         415 (85.0%)
  **Debulking Status**                        
   Missing                                   2
   Optimal; no macroscopic disease           223 (45.9%)
   Optimal; macroscopic disease \<1 cm       140 (28.8%)
   Optimal; macroscopic disease cm unknown   69 (14.2%)
   Sub-optimal; macroscopic disease ≥1 cm    51 (10.5%)
   Unknown                                   3 (0.6%)

EGFR localization to membrane or cytoplasm is not associated with ovarian cancer stage, grade, or overall survival {#s2_2}
------------------------------------------------------------------------------------------------------------------

We analyzed EGFR staining in our patient cohort via multiple approaches. First, we identified staining differences based on localization, as has been reported previously \[[@R9], [@R15]-[@R17]\]. We scored tissue spots as negative, membranous, or cytoplasmic (Figure [1](#F1){ref-type="fig"}). We found 254 patients with membranous stain, 174 patients with cytoplasmic stain and 60 without staining. Membranous expression of EGFR has been linked to elevated proliferation as well as higher stage and grade in some other studies \[[@R9], [@R18]-[@R21]\], but in our cohort, we found no significant correlation with tumor stage or grade when comparing membranous stain to cytoplasmic and unstained patient tissue specimens (Table [2](#T2){ref-type="table"}). We also assessed the relationship between membranous EGFR staining localization and patient survival, but did not find a significant difference for overall survival. We further found no significant difference for overall survival or an elevation in hazard ratio when using the Cox proportional hazard model and adjusting for stage and debulking status, which have previously been established as the major clinical predictors of outcome for this cohort \[[@R22]\] (Table [3](#T3){ref-type="table"}). Comparing unstained *versus* stained cores (grouping cytoplasmic and membranous staining together) also failed to produce a statistically significant association with tumor stage or grade, association with survival, or elevated hazard ratio using the same statistical methods (not shown).

![EGFR staining scored by localization in patient samples\
Representative stains for negative, cytoplasmic, and membranous stain are shown. All scale bars 100 µm.](ganc-08-589-g001){#F1}

###### Analysis based on EGFR staining localization

                      membranous   Non-membranous/negative
  ------------------- ------------ -------------------------
  **Staining**                     
  EGFR                254          234
  Histology                        
  High Grade Serous   186          167
  Nonserous           68           67
                                   *p* = 0.720
  **Stage**                        
  Early (1&2)         59           53
  Advanced (3&4)      195          181
                                   *p* = 0.965
  **Grade**                        
  Low (1)             17           14
  High (2&3)          237          220
                                   *p* = 0.892

###### Cox proportional hazard model for membranous staining

  Cox Hazard Ratio (OS)              Membranous stain   
  ---------------------------------- ------------------ ----------
  Unadjusted                         HR (CI 95%)        p-value
  EGFR: Membranous Stain             0.95 (0.77-1.18)   0.627
  Adjusted for Stage and Debulking                      
  EGFR: Membranous Stain             0.94 (0.76-1.17)   0.573
  Stage: Advanced (3&4)              3.31 (2.39-4.59)   7.30e-13
  Debulking: Optimal                 2.04 (1.48-2.80)   1.11e-5

Dichotomized low *versus* high EGFR expression is not prognostic for survival {#s2_3}
-----------------------------------------------------------------------------

In a separate analysis we assessed EGFR expression based on stain intensity using an automated image analysis algorithm. Calculated percent positivity scores reflect the percent of pixels exceeding a staining intensity threshold in the algorithm. Following established protocols \[[@R19], [@R21]\], we dichotomized the samples into \<10% positivity (n=199) and ≥10% positivity (n=289) (Figure [2](#F2){ref-type="fig"}), but found no significant association of dichotomized EGFR staining with tumor histology (high-grade serous *versus* nonserous), stage, grade (Table [4](#T4){ref-type="table"}), or patient survival (Table [5](#T5){ref-type="table"}). We also found that positive staining for EGFR had no significant correlation with any of the other histotypes, including endometrioid, clear cell, mucinous, or low grade serous (data not shown).

![EGFR staining scored by image analysis\
Scores were calculated by an automated image analysis algorithm based on staining intensity and % positivity. Staining was then dichotomized into two categories: low (\<10%) and high (≥10%). Representative examples for low and high staining are shown. All scale bars 100 µm.](ganc-08-589-g002){#F2}

###### Analysis based on EGFR staining positivity

                      Positivity   
  ------------------- ------------ -------------
  **Staining**                     
  EGFR                199          289
  **Histology**                    
  High Grade Serous   142          211
  Nonserous           57           78
                                   *p* = 0.765
  **Stage**                        
  Early (1&2)         45           67
  Advanced (3&4)      154          222
                                   *p* = 0.970
  **Grade**                        
  Low (1)             8            23
  High (2&3)          191          266
                                   *p* = 0.118

###### Cox proportional hazard model for staining ≥10% positivity

  Cox Hazard Ratio (OS)                  Positivity ≥10%    
  -------------------------------------- ------------------ ----------
  **Unadjusted**                         HR (CI 95%)        p-value
  EGFR: ≥10%                             0.94 (0.76-1.17)   0.576
  **Adjusted for Stage and Debulking**                      
  EGFR: ≥10%                             0.95 (0.76-1.19)   0.655
  Stage: Advanced (3&4)                  3.32 (2.40-4.61)   6.40e-13
  Debulking: Optimal                     2.02 (1.47-2.78)   1.66e-5

Literature review {#s2_4}
-----------------

To place these null results in the context of prior studies examining EGFR protein expression as a prognostic biomarker in ovarian cancer we have reviewed the current literature (summarized in Table [6](#T6){ref-type="table"}). Overall we find little consensus in the approaches to validate EGFR expression as a prognostic marker. Reported positive staining in ovarian tumor tissue varied widely, ranging from 9% \[[@R23], [@R24]\] to 88% \[[@R9]\]; contributing reasons could be differences in antibodies, tissue processing, staining techniques, and patient populations, as well as methodological differences in scoring of the EGFR tissue staining. While common histology scoring systems have been applied by some research groups, accounting for intensity and positivity, the specific details of these approaches have varied, which could substantially impact the overall analysis. Similar to our approach, some studies dichotomized staining into two groups, below and above 10% positivity \[[@R16], [@R19], [@R21], [@R25], [@R26]\], while others chose the more classic 2+ and 3+ score calculated from intensity and positivity \[[@R15], [@R18], [@R27]-[@R30]\] or have defined \>1% stained cells as positive \[[@R20], [@R31], [@R32]\]. Ultimately, all of these thresholds are somewhat arbitrary as there has been no defined biological rationale proposed to justify which staining levels would indicate a significantly different tumor phenotype.

###### Current literature including ovarian cancer patient tissue and EGFR staining (2000-2016)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Source \[citation\]                 N     Country of origin   Antibody                                           Scoring method                                                                                       Summary of results associated with EGFR expression
  ----------------------------------- ----- ------------------- -------------------------------------------------- ---------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  Alshenawy, H.A. 2010 \[[@R29]\]     120   Egypt               Monoclonal Clone 2-18C9\                           Percent positivity and Intensity                                                                     Significantly poorer OS
                                                                Pharm Dx (Dako) IHC                                                                                                                                     

  Brustmann, H. 2008 \[[@R30]\]       50    Austria             Monoclonal NCL-EGFR-384 Novocastra 1:150 IHC       Percent positivity and Intensity, Membrane localization, Large tissue sections, Serous tumors only   Significantly poorer OS

  Castellvi, J. 2006 \[[@R23]\]       75    Spain               Monoclonal DakoCytomation 1:100 IHC                Positivity Membrane localization                                                                     No significant association with OS

  Davies, S. 2014 \[[@R18]\]          202   USA, New Mexico     Monoclonal clone 3C6, IHC                          Percent positivity and Intensity Membrane localization                                               No significant association with PFS

  Despierre, E. 2015 \[[@R41]\]       218   Multicenter\        Cell signaling 1:50                                Percent positivity and Intensity Membrane localization                                               No significant association with OS
                                            Europe                                                                                                                                                                      

  Demir, L 2014 \[[@R31]\]            82    Turkey              Monoclonal, clone EP38Y Abcam IHC                  Percent positivity Membrane localization                                                             No significant association with OS

  Elie, C. 2004 \[[@R26]\]            93    France              Monoclonal clone EGFR.113 Tebu 1:10 IHC            Positivity Membrane localization FIGO III or IV                                                      No significant association with OS

  Engelstaedter, V. 2012 \[[@R34]\]   217   Germany             Monoclonal, clone 3C6 Ventana IHC                  Positivity Membrane localization FIGO III                                                            No significant association with OS

  Fujiwara, S. 2012 \[[@R28]\]        162   Japan               Pharm Dx (Dako) IHC                                Percent positivity and Intensity                                                                     No significant association with OS\
                                                                                                                                                                                                                        Significantly poorer PFS if co-expressed with GRP30\
                                                                                                                                                                                                                        Significantly higher expression in tumor\
                                                                                                                                                                                                                        versus borderline malignancy (n=10)

  de Graeff, P. 2008 \[[@R19]\]       232   Netherlands         no source IHC                                      Percent positivity Membrane localization                                                             No significant association with OS\
                                                                                                                                                                                                                        Significant positivity in non-serous tumors

  Lassus, H. 2006 \[[@R35]\]          379   Finland             Monoclonal NCL-EGFR Novocastra 1:150 IHC           Positivity Membrane localization\                                                                    Significantly poorer OS and DFS
                                                                                                                   Serous tumors only                                                                                   

  Lee, C.H. 2005 \[[@R24]\]           103   Canada              Monoclonal Clone 2-18C9 Dako IHC                   Percent positivity FIGO III or IV                                                                    No significant association with DFS

  Lin, C. 2009 \[[@R15]\]             185   Taiwan              Monoclonal, clone E30 Dako 1:25 IHC                Percent positivity and Intensity                                                                     Significantly higher expression in serous, endometrioid, clear cell, and mucinous tumors than normal tissue

  Nielsen, J.S 2004 \[[@R44]\]        783   Denmark             Monoclonal, clone 113 Novocastra 1:40 IHC          Percent positivity Large tissue sections                                                             No significant association with OS in univariate, significantly poorer OS in multivariate analysis, adjusting for age, FIGO stage, grade, subtype

  Noske, A. 2011 \[[@R32]\]           121   Germany             Monoclonal Clone 5b7 Ventana Medical Systems IHC   Percent positivity Membrane localization                                                             Significantly poorer OS for membrane stain and serous carcinoma

  Psyrri, A. 2005 \[[@R16]\]          150   Greece              Monoclonal, clone H11 DAKO 1:50 IF                 Percent positivity and Intensity Nuclear localization FIGO III or IV                                 Significantly poorer OS and DFS in univariate and multivariate analysis, adjusting for FIGO stage, grade, residual disease and chemotherapy response

  Raspollini, M.R. 2005 \[[@R36]\]    60    Italy               Monoclonal Clone 31G7 Ventana Medical Systems      Positivity Membrane localization\                                                                    No significant association with OS
                                                                                                                   Large tissue sections FIGO IIIC only                                                                 

  Skírnisdóttir, I. 2004 \[[@R21]\]   212   Sweden              Monoclonal, clone 113 Novocastra IHC               Percent positivity\                                                                                  No significant association with OS\
                                                                                                                   Membrane localization                                                                                Significantly poorer DFS for FIGO I-II\
                                                                                                                                                                                                                        Higher positivity in serous compared to\
                                                                                                                                                                                                                        clear cell carcinoma

  Stadlmann, S. 2006 \[[@R20]\]       80    Switzerland         Monoclonal, clone 2-18C9 PharmDX (Dako) IHC        Percent positivity Membrane localization Serous tumors only                                          Significantly associated with EGFR amplification in both primary and recurring tumors

  Tanaka, Y. 2011 \[[@R42]\]          102   Japan               Pharm Dx (Dako) IHC                                Percent positivity FIGO II, III, IV                                                                  No significant association with OS

  Wang, K. 2016 \[[@R37]\]            242   China               Polyclonal Santa Cruz IHC                          Percent positivity and Intensity                                                                     No significant association with OS\
                                                                                                                                                                                                                        Significantly poorer OS associated with tumor stroma expression

  Wittinger, M. 2011 \[[@R25]\]       144   Austria             Polyclonal Santa Cruz 1:100 IHC                    Percent positivity and Intensity                                                                     Significantly poorer OS

  Xia, W. 2009 \[[@R43]\]             221   USA, Texas          Nuclear stain: Polyclonal Upstate 1:150\           Percent positivity and Intensity                                                                     Significantly poorer OS with nuclear localization\
                                                                Cytoplasmic stain: Clone EGFR.25 Novocastra IHC                                                                                                         No significant association with OS in cytoplasmic stain

  Zhang, M 2015 \[[@R27]\]            161   China               Polyclonal Santa Cruz 1:100 IHC                    Percent positivity and Intensity\                                                                    Significantly poorer OS\
                                                                                                                   Membrane localization                                                                                Significantly higher expression in serous and endometrioid tumors
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OS- overall survival, DFS -- disease free survival, PFS -- progression free survival, HR -- hazard ratio. IHC- immunohistochemistry, IF- immunofluorescence

A majority of studies applying morphological criteria have described their tissue as EGFR positive when staining occurs in the cell membrane \[[@R9], [@R18]-[@R21], [@R23], [@R26], [@R27], [@R30]-[@R36]\], while others have included cytoplasmic staining or mixed cytoplasmic/membranous staining \[[@R15], [@R24], [@R28], [@R29]\] or have specifically evaluated staining in the tumor stroma \[[@R37]\]. However, there remain unanswered questions about the biological significance of the predominant staining localization. While membranous positioning of EGFR could allow for higher activation through growth factors and thus more activation of downstream signaling pathways \[[@R38]\], there is also evidence in other tumors that the cytoplasmic localization is associated with an equally malignant phenotype \[[@R39], [@R40]\].

Despite differing approaches to detecting and scoring EGFR, the majority of studies, similarly to the present report, have concluded that EGFR staining is likely to be of no or only modest utility as a prognostic marker \[[@R18], [@R19], [@R23], [@R24], [@R26], [@R31], [@R34], [@R36], [@R41], [@R42]\]. Few studies showed a significant association of EGFR with poorer overall or disease free survival or with progression in their general patient population, although some significant differences were noted in patient subsets or with multivariate analyses \[[@R21], [@R25], [@R29], [@R30], [@R32], [@R43], [@R44]\] (Table [6](#T6){ref-type="table"}). For example in a large Danish study, Nielsen et al. reported significant association of EGFR with poorer overall survival after adjusting for age, FIGO stage, grade, and histotype. However, the HR was modest (1.2), and in a model with more robust molecular markers p53 and HER-2, EGFR offered no additional prognostic effect; the authors concluded that EGFR does not represent an important prognostic factor \[[@R44]\]. In a Swedish study, EGFR staining was significantly associated with progression free survival only in FIGO stage I-II patients \[[@R21]\]. Two studies found EGFR staining to be associated with poorer overall survival in cohorts limited to patients with ovarian serous carcinoma \[[@R30], [@R35]\]. In a Japanese study, while EGFR staining alone was not prognostic for overall or progression free survival, co-staining of EGFR with another marker, GPR30, was significantly associated with poorer progression free survival \[[@R28]\]. In other studies, significant associations of EGFR with overall survival were seen when using immunofluorescence staining \[[@R16]\], when detecting membranous staining using a novel antibody recognizing the intracellular domain of EGFR \[[@R32]\], or when scoring nuclear stain specifically \[[@R29], [@R43]\].

The potential use of EGFR as a therapeutic target and tissue staining as a method of patient stratification to select for specific treatments has prompted studies to evaluate possible differences in EGFR protein expression within the various histotypes. Although some studies reported significant differences in staining frequencies by histology, for example in serous tumors compared to clear cell histology \[[@R21]\], serous and endometrioid compared to other histotypes \[[@R27]\], mucinous and serous tumors compared to cystadenomas \[[@R9]\], or in tumors compared to borderline malignancies \[[@R28]\], most found no significant differences in EGFR staining among histotypes \[[@R15], [@R17], [@R23], [@R32], [@R44]\], as in the present study.

Overall, our results and the review of the literature suggest that the prognostic value of EGFR in ovarian cancer cannot be determined by immunohistochemistry alone. Increased biological understanding of EGFR localization and/or expression levels, as well as improvements in antibodies and image analysis methods, will be necessary to develop specific analysis tools towards improved patient management.

DISCUSSION {#s3}
==========

Our study represents one of the largest ovarian cancer patient cohorts assessed by immunohistochemistry for EGFR protein expression and localization. In our previous work with this patient cohort, we found a serine protease inhibitor (SPINK1) to be a prognostic factor for nonserous ovarian tumors; subsequent studies using cell culture models determined that SPINK1-driven ovarian cancer cell proliferation is mediated through EGFR signaling pathways \[[@R45]\]. Given the association between SPINK1 expression and survival for a subset of patients, we assessed potential interrelation between SPINK1 and EGFR staining, but did not find any significant associations (data not shown). Here, we investigated the use of EGFR staining as a single prognostic marker in the same ovarian cancer patient cohort. We found almost 90% of our tumor tissue samples to have some EGFR staining; however, after multiple analyses, we found no significant association with indicators for progression (grade or stage), survival, or histotype. These findings are in general accordance with what has been described in most of the previous studies when looking at overall populations and EGFR staining as a prognostic marker in ovarian cancer, while some studies using smaller patient cohorts or restricted patient subsets have reported statistically significant associations (Table [6](#T6){ref-type="table"}).

Subcellular localization of EGFR has been associated with outcome in a number of other tumor types. In pancreatic cancer, shorter overall survival was found for patients with EGFR staining of the tumor cell cytoplasm \[[@R39], [@R46]\]. In contrast to many other tumors, EGFR localization to the membrane was found to be significantly associated with better patient survival in renal cell carcinoma \[[@R47], [@R48]\]. In NSCLC, there is some evidence that nuclear EGFR staining may be associated with poor survival \[[@R49]\]. In addition, EGFR membranous expression could be a useful predictive tool for targeted EGFR inhibitor therapy in patients with NSCLC \[[@R50]\]. Differences in associations between tumor types may be due to differential effects of growth factor stimulation with internalized EGFR \[[@R39], [@R51]\]. The literature on ovarian cancer patients reports cytoplasmic membranous \[[@R21]\], predominant membranous \[[@R9]\], or combined cytoplasmic and membranous stain \[[@R28]\], but we found that dichotomizing the tissue samples based on membranous and cytoplasmic staining did not reveal significant correlation with stage, grade, or patient survival.

While EGFR signaling is involved in promoting ovarian cancer cell proliferation \[[@R45]\], the results of the present study are in agreement with a number of previous analyses showing that EGFR tumor tissue staining by immunohistochemistry may be unpredictive of tumor progression \[[@R18], [@R19], [@R28], [@R33], [@R52]\]. Alternatives may be to analyze samples via an immunofluorescence staining approach \[[@R16]\], which may provide higher sensitivity and a broader dynamic range relative to immunohistochemistry methods, or by fluorescence in situ hybridization (FISH), which can detect EGFR gene amplification and copy number gain, a measure potentially more closely associated with poor prognosis in ovarian cancer \[[@R13], [@R20], [@R35]\].

Efforts using EGFR inhibitors in ovarian cancer patient clinical trials within the general patient population have had only very limited success \[[@R8], [@R38], [@R53]\]. One possible explanation is that despite possessing highly elevated levels of EGFR protein, ovarian tumors present only rarely with EGFR mutations, while response to EGFR TKIs in other tumor types such as non-small cell lung cancer (NSCLC) is highly dependent on the presence of mutated EGFR \[[@R54], [@R55]\]. Mutational screening is also a useful approach to patient stratification in metastatic colorectal carcinoma, where mutations in EGFR pathway mediators *KRAS*, *NRAS*, *BRAF*, and *PIK3CA* are negative predictors of efficacy for anti-EGFR therapeutics \[[@R56]-[@R58]\]. However, such mutations are relatively rare in ovarian cancer, and did not predict drug response in the concluded phase III trial of erlotinib in ovarian cancer patients \[[@R41]\]. There may be room for applications of yet untested EGFR modulating drugs or strategies in ovarian cancer patients, but this will likely require a different approach for patient stratification, as current investigation shows that EGFR staining is not consistently associated with tumor response \[[@R13]\].

Other immunohistochemical markers downstream of EGFR signaling pathways such as pAKT, pERK (also known as pMAPK), or pSTAT3 could potentially be more useful as prognostic markers and might also help to stratify ovarian cancer patient populations for treatment with TKIs \[[@R59]\]. These mediators become phosphorylated in the process of activation which can be assessed by tissue staining, but studies are conflicting in terms of the utility of these proteins as prognostic biomarkers. In ovarian cancer patients, high pAKT, high pERK, or their combination have been linked with poor overall survival and progression free survival \[[@R41], [@R42], [@R60]\]; however, contrasting studies have failed to find significant associations of pAKT or pERK with survival \[[@R19], [@R23], [@R61]\]. High pSTAT3 has also been associated with poorer overall survival in ovarian cancer \[[@R62]\]. While limited studies to date have not been encouraging with regard to the use of pAKT or pERK to predict TKI response in ovarian cancer patients \[[@R41]\], in some other tumor types these markers have shown more promise. In NSCLC for example, high levels of pAKT predicted better response to TKI (gefinitinib) therapy and significantly longer time to progression in one study \[[@R63]\], and in another study, pAKT and pSTAT3 both showed a trend towards association with longer time to progression on gefitinib \[[@R64]\]. While data evaluating the predictive potential of EGFR and related markers in ovarian cancer have thus far not been encouraging, it remains possible that EGFR expression or gene copy number in combination with other markers may yet become useful for stratification of response to treatment.

A strength of the present study is the large patient cohort and the extensively documented patient data that includes clinical history and clinico-pathological details. An additional strength is the application of multiple methods of scoring and analysis enabling relevant comparison with prior studies. Limitations include the relative geographic and ethnic homogeneity of our patient cohort, as some contrasting findings in other studies may reflect population-specific differences.

In conclusion, our results and the current literature indicate that EGFR may not be a robust or generally applicable prognostic immunohistochemical marker for ovarian cancer patients. The success in other cancer types of alternative biomarkers, including activated proteins downstream of EGFR signaling, EGFR mutations and mutations in other pathway genes, may suggest more fruitful directions for identifying potential surrogate markers of EGFR expression, activation, and treatment response in ovarian cancer.

MATERIALS AND METHODS {#s4}
=====================

Study population {#s4_1}
----------------

Tumor biospecimens used for this study were derived from a Mayo Clinic consecutive cohort of 570 patients. Study eligibility included women 20 years or older diagnosed with pathologically confirmed invasive epithelial ovarian, primary peritoneal, or fallopian tube cancer. Patients were enrolled from 1999 to 2009 and were drawn from Mayo Clinic\'s gynecologic surgery and medical oncology departments. Patients provided written informed consent and protocol procedures and patient contact materials were reviewed and approved by the Institutional Review Board of the Mayo Clinic. All medical records were reviewed and data extracted by experienced research nurses under supervision of gynecologic and medical oncologists. Further details about this cohort have been described previously \[[@R65], [@R66]\].

Tissue microarrays and immunohistochemistry {#s4_2}
-------------------------------------------

Formalin-fixed, paraffin embedded (FFPE) tumor biospecimens were assembled into five tissue microarrays. Specimen collection and eligibility was coordinated through the Mayo Clinic Ovarian Cancer SPORE and has been previously described \[[@R45], [@R65], [@R66]\]. Briefly, tissue cores (0.6mm diameter) were assembled at random placing 350 spots (three cores per patient tumor) with the automated Beecher Instruments ATA-27 arrayer. 5 um sections were cut and mounted on charged slides. Following deparaffinization and rehydration, antigen was retrieved in citrate buffer, endogenous peroxidase was blocked with 3% H~2~O2 and slides were incubated with serum-free protein block (Dako). Slides were then stained for 1 h at room temperature with anti-EGFR \[EP38Y\] monoclonal antibody (Abcam \# ab52894, dilution 1:200) followed by 30 min with secondary anti-rabbit labeled polymer/horse radish peroxidase conjugate (Dako \#K4003) finally the color was developed using 3,3′-diaminobenzidine (DAB, EnVision+, Dako).

Stained slides were scanned (ScanScope scanner, Aperio Technologies, Vista, CA), and tissue quality and presence of tumor was determined by CM in consultation with a gynecologic pathologist (AN). Spots with more than 50% tissue damage or fewer than 30 tumor cells were excluded from analysis. Out of 570 patients, 63 were excluded due to missing or damaged tissue in all cores, and 19 were excluded for histological criteria (tumor morphology classified as non-epithelial ovarian, borderline, or unknown). Staining was assessed by scoring tissue cores according to localization (none, cytoplasmic, or membranous; if both cytoplasmic and membranous stain were present the spot was scored as membranous) and a positive pixel count algorithm which gives numeric value corresponding to the % of pixels with moderate or strong staining (Image Scope Software, Aperio Technologies; settings: Hue Value 0.1, Hue width 0.5, Color Saturation Threshold 0.04, lwp (High) 225, lwp(low)=lp(High) 165, lp(low)=Isp(High) 100, Isp(low) 0, Inp(High) -1). The resulting percentages were then dichotomized and defined as low EGFR (\<10%) and high EGFR (≥10%). Three cores per patient were stained and the maximum stain value per patient was used for analysis.

Statistical analysis {#s4_3}
--------------------

Statistical analyses were done using the R statistical software package (version 3.1.1). Associations between EGFR and morphology, stage, and grade were assessed via contingency tables and the Chi-square test. Association of overall survival was assessed via Kaplan Meier curves and Cox proportional hazards models. Models were run both unadjusted and adjusted for stage (early vs. advanced), and debulking status (sub-optimal vs. optimal).

We acknowledge Brandy Edenfield of the Mayo Clinic Department of Cancer Biology histology shared resource for excellent technical support. Construction of the TMAs, collection of annotated clinical data and statistical analyses were supported by the Mayo Clinic Ovarian Cancer SPORE P50 CA136393 and R01 CA122443 to ELG. The study was supported by R21 CA177865 and RO1 CA154387 to ESR.

**AUTHOR CONTRIBUTIONS**

CM and ESR designed the study, interpreted results, performed literature reviews and drafted the manuscript. TMAs were constructed by ELG and GLK, and were obtained along with clinicopathological data through a biospecimens resource directed by KRK. CM scored TMAs and analyzed data in consultation with AN. ALO, KMG, and MJM performed statistical analysis and contributed to manuscript preparation. KRK, ELG, AJ, and DCR provided advice on analyses and contributed to manuscript preparation. All authors approved the final manuscript.

**CONFLICTS OF INTEREST**

The authors have no conflicts of interest to declare.

**FUNDING**

This work was supported by National Cancer Institute grants R21CA177865 and R01CA154387 to E.S.R. and by the Mayo Clinic SPORE in Ovarian Cancer grant P50CA136393.

EGFR

:   Epidermal growth factor receptor

SPINK1

:   serine protease inhibitor kazal type 1
